C ompared with peers, patients with rheumatoid arthritis (RA) have higher rates of cardiovascular disease (CVD) events including myocardial infarction, stroke, and heart failure, 1 conditions causally linked to hypertension. Hypertension (HTN) affects 50% of people older than 55 years, yet nearly half of adults with known HTN do not have it under control. 2 Hypertension is the most frequent comorbidity in RA 3, 4 and is a major determinant of organ damage and mortality. 5 Studies describe CVD event or CVD mortality risk ratios for HTN between 2.8 and 4.1 in RA, notably higher than the 1.3 to 1.7 independent RA risk for CVD in many studies. 1, [6] [7] [8] Nevertheless, we previously reported that among patients meeting criteria for incident HTN (i.e., newly developed, without prior diagnosis or treatment), RA patients were 29% less likely than peers without RA to be diagnosed with HTN, despite more frequent visits. 9 Others have also reported high prevalence of uncontrolled HTN in RA. [5] [6] [7] [10] [11] [12] Blood pressures (BPs) are routinely measured in rheumatology clinics where RA patients may receive most of their care. Nationally, 73% of 2.6 million annual provider visits for RA occurred in specialty clinics. 13 Rheumatology visits equaled or exceeded primary care visits for half of the Medicare patients with RA.
14 Despite routine BP measurement at rheumatology visits, studies show that many rheumatologists are unwilling to treat HTN. 15, 16 Recent quality measures 17 call not only for BP assessment but also for "timely BP follow-up" across group practices defined as remeasurement within 4 weeks. A recent international rheumatology expert panel nearly reached consensus recommending that rheumatologists communicate findings of high BPs to ensure such primary care follow-up. 18 Recognizing HTN as a highly prevalent comorbidity and a highly reversible risk factor for CVD morbidity and mortality, we sought to examine how rheumatologists documented communication about high BP or HTN during RA clinic visits. We termed this "BP communication." We hypothesized that higher BP measurements would predict more BP-related communication with RA patients in rheumatology clinic visits. Given that increased BP magnitude increases CVD risk, our objectives were to examine the relationship between the magnitude of BP elevation (none = ideal normotension, mild = pre-HTN, moderate = stage I, or severe = stage II HTN per clinical definitions at the time) 19 on the likelihood of documented BP communication in RA visit notes and to examine other predictors of BP communication.
MATERIALS AND METHODS

Sample
Using electronic health record (EHR) searches, we first identified potential RA patients by the presence of 2 or more International Classification of Diseases, Ninth Revision codes for RA (714.0-714.33, 714.4, 714.80, 714.81, 714.89) 20, 21 in a large academic multispecialty health system between 2008 and 2011. We then identified an RA cohort receiving regular primary and rheumatology care (Fig. 1) . Regular care was defined as having at least 1 ambulatory visit in primary care and 1 in rheumatology in 24 months, including at least 1 visit in the most recent 12 months adapting a published Wisconsin Collaborative for Healthcare Quality metric. 22 This definition guaranteed that an individual included in the study was receiving both specialty and primary care, which allowed us to review continuous BP trends over time in both contexts. Visits with patients who were pregnant during the observation period and visits in the emergency department were excluded to avoid secondary causes of HTN from pregnancy, pain, or trauma. Visits with patients who did not have RA per rheumatologist notes were also excluded through a later manual abstraction item.
Next, we restricted eligibility to include only RA patients who met diagnostic criteria for uncontrolled HTN defined by EHR algorithms using the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure criteria, per clinical standards at the time. 19 "Uncontrolled HTN" included those meeting incident (undiagnosed) HTN criteria and those with prior diagnosis or treatment whose BPs remained elevated. An individual was classified as having incident HTN if they had 2 dates of having an ambulatory BP greater than 160/100 mm Hg or 3 greater than or equal to 140/90 mm Hg (or 130/80 for those with comorbid diabetes) in the absence of a prior HTN diagnosis code or medication. 19, 23 Elevated BP readings had to be at least 30 days apart and within 2 years. Likewise, those with prevalent HTN identified by diagnosis codes for HTN 23 or by the use of any baseline antihypertensive 19 Subjects were followed up longitudinally and censored at the earliest date of the following: discontinuity of regular care (no visits in >12 months), death, BP normalization, or January 2012. We identified all rheumatology clinic RA visits for eligible patients from their entry date through their end date to determine whether BP communication occurred at each rheumatology visit.
Ethics and Approval
We received approval for this medical record review study (University of Wisconsin Health Sciences Institutional Review Board 2012-0053) from the Minimal Risk Institutional Review Board with a Health Insurance Portability and Accountability Act waiver of consent.
Electronic Health Record Review for Primary Outcome
We manually abstracted each face-to-face rheumatology visit that occurred after an RA patient met entry criteria for uncontrolled HTN until the date of control or censorship. Trained medical abstractors used a predefined electronic abstraction tool to review all eligible RA visit notes by rheumatology providers.
Abstractors reviewed the clinician's encounter visit note, all electronic orders, and patient after-visit instructions for any written documentation about BP or HTN. The abstraction tool contained 13 items detailing communication about BP or HTN to the patient or primary care provider (PCP) ( Table 1 ). The tool asked about the presence of any text beyond vital sign documentation regarding 4 areas: (1) current or prior high BP or HTN; (2) BP interpretation (elevated/high), rechecks, or reviewed for additional or previous values; (3) recommendation of patient or PCP follow-up; and (4) review of numeric BP treatment goals or medications with the patient or PCP. "BP communication" was met by any of these 13 items. On 5% audits, abstractors were required to demonstrate interobserver agreement for BP communication for quality assurance. 24 After every 200 charts were reviewed by an individual abstractor, quality assurance audits were performed by a second reviewer who reabstracted 10 charts to ensure agreement by consensus. This approach resulted in interrater agreement of greater than 90% across BP communication items.
Explanatory Variable and Covariates
Blood pressure magnitude, as defined by the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 19 and the American Heart Association BP stages, was assessed through EHR queries of longitudinal BP trends. The categorical magnitude of the BP at a given visit was the main explanatory variable. 19 Using this definition, a visit with BP <120/80 mm Hg was considered ideal normotensive, BP ≥120/80 and <140/90 mm Hg was prehypertensive, BP ≥140/90 and <160/100 mm Hg was stage I hypertensive, and BP ≥160/100 was stage II hypertensive.
Covariates for the study included patient sociodemographics during the baseline year, such as age, sex, race, language, marital status, and ever receiving Medicaid, as a socioeconomic proxy. Behavioral health traits included tobacco history and quartiles of body mass index (BMI). Comorbidities included prior CVD (which included history of ischemic heart disease, congestive heart failure, peripheral vascular disease, transient ischemic attack, or stroke), chronic kidney disease, end-stage renal disease, diabetes, and hyperlipidemia extrapolated using validated algorithms. [25] [26] [27] We also calculated a composite score using the Johns Hopkins Adjusted Clinical Group (ACG) system (version 10). 28 The ACG calculates a score based on common morbidity patterns determined by 224 different clinical groupings. In this system, an individual scoring 1 is predicted to have average, whereas an individual scoring more than 1 would be predicted to have greater than average, composite health needs or illness burden. We created dummy variables to account for calendar year and clinic. 
Analysis
For descriptive statistics comparing visits with normotension, pre-HTN, and stages I and II BP elevations, we used the χ 2 test for categorical variable comparisons and analysis of variance for continuous variables. P < 0.05 was considered significant. Correlation matrices showed no evidence of collinearity for covariates. Multivariate logistic regression was used to analyze the relationship between explanatory variables and BP communication. We used the Stata margins command to estimate adjusted predicted probabilities (APPs) based on the recycled predictions approach. Odds ratios (ORs) and 95% confidence intervals (CIs) for BP communication by BP magnitude were calculated using robust estimates of the variance that account for clustering. Sensitivity testing models were reanalyzed to account for clustering by provider, and predictors did not differ.
Patient sample selection and data variable creation were conducted using SAS version 9.1.3 (SAS Institute, Inc., Cary, NC); statistical analysis was conducted using Stata version 12.0 (StataCorp, College Station, TX).
RESULTS
Among 1267 potential RA patients receiving both primary and specialty care in our health system, 40% experienced visits with high BPs. Among 426 rheumatologist-confirmed RA patients with uncontrolled HTN, 232 (18%) also met incident HTN criteria; by definition all had uncontrolled HTN (Fig. 1) . Among visits of RA patients with uncontrolled HTN, we observed a mean patient age of 61.6 (SD, 12.3) years, and female patients comprised 76% of the visits (Table 2) . Overall, 11% were current smokers, and greater than 20% had a prior CVD diagnosis. In total, these 426 RA patients had 2677 visits abstracted to examine BP communication.
Visit-level BPs in this cohort varied widely. Among the 2677 abstracted visits, participants had a normal BP at 20% of these visits, pre-HTN in 45% of visits, and BP was stage I in 32% and stage II in 11% of visits. Compared with normotensive patient encounters, visits with BPs meeting criteria for stage I or stage II HTN occurred significantly more often in visits with patients who were older, black, tobacco users, and in a higher BMI quartile ( Table 2) . (Table 3) , although there was a positive test for linear trend (P < 0.001). Results were similar when analyzed clustering on provider (data not shown).
Other Predictors of BP communication
In the adjusted OR model, active tobacco users were least likely to have BP communication (OR, 0.4; CI, 0.26-0.63; Table 3 ). Those in the highest ACG quartile for ACG comorbidity scores had lower odds of BP communication compared with the lowest ACG quartile (OR, 0.43; CI, 0.32-0.57). Patients who were older than 80 years, unmarried, ever on Medicaid, or in the highest BMI quartile or had prevalent CVD were more likely to have BP communication documented.
When examining an adjusted model on visits with stage I or II BP elevation as shown in Table 4 , current tobacco use and increasing complexity indicated by ACG quartile predicted less likely BP communication. In contrast, the highest BMI quartile and presence of baseline CVD both predicted more BP communication.
Describing BP Communication Types
In total, 601 (22%) of 2677 observed visits contained any BP communication. Figure 3 shows that even when scaling only to the 601 visits with BP communication, 70% of the time providers listed HTN as a preexisting comorbidity, and 25% simply interpreted that the current visit BP was elevated. Only 102 visit notes included recommendations for patients or their PCPs to follow up elevated BPs, fewer than 10% of the 1285 total eligible visits with high BPs. Again, scaled to the 601 visits with BP communication, only 8% documented reviewing prior BP trends. Six percent of visit notes clarified BP medication instructions, and fewer than 1% (n = 4 each) documented discussing numeric BP targets or discussed a new BP medication prescription.
DISCUSSION
We found that documented communication about HTN or BP rarely occurred in visits with RA patients who had uncontrolled hypertension despite their increased CVD risk. 6, 7, 29 Discussions about high BP were documented in fewer than 1 in 3 RA visit notes even when severely elevated (≥160/100 mm Hg). At this BP range, using estimates from the general population with 1 CVD risk factor, experts predict that providers need to treat 7 patients to prevent 1 cardiovascular event. 30 This highlights an opportunity for improving outcomes by managing or referring RA patients with high BPs back to primary care for HTN management. Blood pressure was routinely measured, yet high BPs most often went unmentioned.
In this study, we also reported that despite compounded CVD risk, tobacco users received less BP communication, and only those with the highest BMI and prevalent CVD were more likely to receive BP communication. In a prior study, we also noted lower rates of incident HTN diagnosis in RA patients than peers, with particularly low rates in RA patients who currently use tobacco. 31 In another study, we also reported that only 10% of encounters with RA patients who smoked documented cessation counseling, 32 suggesting that competing priorities alone did not explain gaps in CVD risk factor counseling for either HTN or smoking cessation. Likewise, noting more BP communication after CVD events highlights a missed opportunity to reduce CVD by addressing modifiable risk factors such as HTN before events occur.
Moreover, when documented BP communication did occur in this study, rheumatologists rarely took action. Recommended follow-up for elevated BPs was documented in only 10% of eligible RAvisits. Our findings are similar to a previous study in which only 31% of rheumatologists said they would routinely treat elevated BP. 16 As we have previously reported from interviews, 15 rheumatologists might hesitate to act on BP elevations, even FIGURE 2. Probability of BP communication by visit BP category representing magnitude. The x axis represents visits by American Heart Association BP group, and the y axis demonstrates the percent predicted probability that BP communication occurred at each visit within that BP category.
though PCPs requested that they simply "send patients back" to address HTN and other modifiable risks. This lack of action highlights the opportunity for systematic approaches to help RA clinics connect patients to the BP care and CVD preventive care they need. The Centers for Disease Control and Prevention and the Centers for Medicare & Medicaid Services have called for the use of staff HTN protocols as a way to "save more life years than any other intervention." 33 Staff HTN protocols are proven to improve BP control from 50% nationally to greater than 80% in primary care settings. 34 Such protocols have not been extensively studied in specialty settings such as rheumatology clinics, but they hold potential. Specialty clinic protocols could support timely followup of high BPs as defined by quality metrics using simple new thresholds (BPs ≥140/90 mm Hg for all adults). 35 Blood pressure protocols do not require risk calculations to determine who should be treated, making BP follow-up referrals easier to execute than the "annual CVD risk evaluations" called for by the European League Against Rheumatism and others. 12, 36 Moreover, staffdriven protocols can address group practice quality metrics for BP follow-up without burdening busy rheumatology clinicians. Future studies should test staff BP protocols in rheumatology clinics to address gaps observed in this study.
A strength of our study is that it captured a large number of clinical encounters with RA patients who received both primary and specialty care in the same health network. Presumably, this setting would be an ideal environment for communication by rheumatologists to connect patients back to primary care for BP follow-up, yet this rarely occurred. As with any study, one must also consider limitations. First, given that this was a medical record abstraction study, we recognize that undocumented BP communication discussions would not be captured. However, if an action was not documented, it is less likely to have occurred or to be followed up by the patient or primary provider. Second, as a method, manual abstraction could introduce error, although quality control measures aimed to decrease such errors. 24 Third, our results reflect rheumatology clinics from a single health network. These clinics might not reflect the care practices of other rheumatologists, and BP communication in other specialty clinics was not compared. Likewise, beyond BP and BMI, these clinics did not measure waist circumference representing abdominal fat mass for additional CVD risk estimation, although this would not be customary in most US noncardiology specialty clinics. In addition, we also acknowledge that high BP at a single visit might not indicate HTN. In this study, we did not have access to ambulatory BP data or BPs outside clinic. Still, some authors recently confirmed that variability in BP itself heightens CVD risk in RA, 37 so even intermittent BP elevations likely confer risk and merit discussion with patients. Moreover, in our study, multiple elevated BPs over time were required to meet clinical criteria for HTN, and given known CVD risk in the RA population, recurrent elevated BPs are a risk factor that should be identified and addressed.
Overall, regardless of BP category, most eligible RA visits lacked documented communication about high BPs despite heightened cardiovascular risk in RA patients. Future work should examine systematic approaches to improve identification and referral of high BP and other modifiable risk factors to reduce CVD risk and promote longevity in patients with RA and other rheumatologic conditions.
KEY POINTS
• In this study, documented communication about elevated BPs was discussed in only 22% of visits and only 31% of visits when BP was severely elevated.
• Fewer than 10% of eligible RA visits with uncontrolled HTN resulted in action including a recommendation to follow-up elevated BPs; fewer than 1% resulted in antihypertensive medication initiation or titration.
• Our findings highlight the potential benefits of systematic strategies to facilitate follow-up or management of HTN or other CVD risk factors in at-risk RA populations.
